Skip to main content
Rixt A. Wijma on Muck Rack

Rixt A. Wijma

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rixt A.

Contact Rixt A., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic In Vitro Model

|
By Iain J. Abbott, Elke van Gorp, Rixt A. Wijma
| American Society for Microbiology (ASM)
Pharmacology Iain J. Abbott, Elke van Gorp, Aart van der Meijden, Rixt A. Wijma, Joseph Meletiadis, Jason A. Roberts, Johan W. Mouton, Anton Y. Peleg DOI: 10.1128/AAC.00342-20 ABSTRACT There are limited treatment options for enterococcal urinary tract infections, especially vancomycin-resistant Enterococcus (VRE). Oral fosfomycin is a potential option, although limited data are available guiding dosing and susceptibility. We undertook pharmacodynamic profiling of fosfomycin against E. faecalis and E.
Open in Who Shared Issue with article?

Oral Fosfomycin Efficacy with Variable Urinary Exposures following Single and Multiple Doses against Enterobacterales: the Importance of Heteroresistance for Growth Outcome

|
By Elke van Gorp, Iain J. Abbott, Rixt A. Wijma
| asm.org
Clinical Therapeutics Iain J. Abbott, Elke van Gorp, Rixt A. Wijma, Joseph Meletiadis, Jason A. Roberts, Johan W. Mouton, Anton Y. Peleg DOI: 10.1128/AAC.01982-19 ABSTRACT Oral fosfomycin trometamol is licensed as a single oral dose for the treatment of uncomplicated urinary tract infections, with activity against multidrug-resistant uropathogens. The impact of interindividual variability in urinary concentrations on antimicrobial efficacy, and any benefit of giving multiple doses, is uncertain.
Open in Who Shared Issue with article?
See all 2 articles